Please login to the form below

Medivation

This page shows the latest Medivation news and features for those working in and with pharma, biotech and healthcare.

Pfizer names next CEO as Read retires

One M&A deal that did go through was the $14bn acquisition of Medivation in 2016, though many analysts say the big pharma company overpaid for the firm and its oncology

Latest news

Sanofi sells European generics to Advent for $2.4bn

for Medivation and Actelion.
PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

The two companies hope that the new data will help impart fresh momentum to Xtandi, which was the main asset in Pfizer’s $14bn takeover of Medivation in 2016 but which
Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

French pharma firm offers $105 apiece for the spin-out’s shares. After missing out on earlier bids for Medivation and Actelion, Sanofi has agreed to buy Biogen haematology spin-out ... Medivation in 2016 and was also trumped by Johnson &Johnson after
After some big setbacks, Sanofi talks up its R&D portfolio

However, it has tried and failed to make two pipeline-boosting acquisitions of late, losing out out to rivals bidding for Actelion and Medivation.
Pfizer could raise ‘up to $15bn’ from consumer unit sale

of failed merger attempts with AstraZeneca and Allergan, the takeovers of Hospira and cancer specialist Medivation, and the divestment of Hospira’s infusions unit.

More from news
Approximately 15 fully matching, plus 38 partially matching documents found.

Latest Intelligence

Deal Watch December 2016

Only August 2016 ($21.4bn, including $14bn for the Pfizer Medivation deal) came close. ... Excluding the Shire-Baxalta and Pfizer-Medivation deals, the figure for total (disclosed) upfront payments typically ranges between $1-6bn per month.
Deal Watch August 2016

So the conclusion is that Pfizer is mainly expecting to generate value from Medivation's late stage oncology programme. ... Sanofi sought to take control of Medivation's board using a paper vote.
Deal Watch May 2016

on. Following its rejection of the $9.3bn [$52.5 per share in cash, 36% premium] on the table from Sanofi, Medivation is now open to bids, encouraging competition. ... In the light of this, Sanofi has elected to go hostile and has filed with the SEC
Deal Watch April 2016

Sanofi would like to merge with Medivation as it makes “ strong strategic sense”. ... Unfortunately the Medivation CEO, David Hung, was not interested in a meeting or even hearing Sanofi's proposal.
Pharma deals in August 2015

Licence. 700. BioMarin. Medivation. Talazoparib a PARP inhibitor in P3 for BRCA mutated breast cancer.

More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest appointments

Revolution Medicines appoints Dr Stephen Kelsey

Prior to his time at Onkaido Therapeutics, Kelsey has served in several senior positions at Medivation, Generon and Genentech, where he held the role of vice president, haematology and oncology.
Avanir Pharmaceuticals appoints new president and CEO

He has over 20 years of drug development and commercialisation experience, having previously worked as chief commercial officer for Medivation and in various senior management roles at Johnson &Johnson and Centocor.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Business Director: Competitive Salary Offered

Experienced Medical Writers: Competitive Salary and Benefits

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Manager / Account Director: Competative

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Editorial Manager - MedComms: DOE

Account Director: Competitive Salary Offered

Account Manager- Healthcare Advertising: Negotiable

Senior Editorial Assistant – Greater Manchester: DOE

Senior Account Manager: Competitive Salary Offered

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Associate Medical Director: Excellent PTO, bonus and 401k package

Account Executive/ Senior Account Executive: competitive Salary Offfered

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Principal Health Economist - North-West: Negotiable

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Healthcare Communications Account Directors x 2: Salary TBC

Account Manager: Negotiable

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Systematic Reviewer - Oxford: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?: What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma: Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies: Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...